MX2024002060A - Composicion farmaceutica para tratar tumores solidos. - Google Patents
Composicion farmaceutica para tratar tumores solidos.Info
- Publication number
- MX2024002060A MX2024002060A MX2024002060A MX2024002060A MX2024002060A MX 2024002060 A MX2024002060 A MX 2024002060A MX 2024002060 A MX2024002060 A MX 2024002060A MX 2024002060 A MX2024002060 A MX 2024002060A MX 2024002060 A MX2024002060 A MX 2024002060A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- solid tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021146389 | 2021-09-08 | ||
| PCT/JP2022/033458 WO2023038030A1 (ja) | 2021-09-08 | 2022-09-06 | 固形腫瘍治療用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002060A true MX2024002060A (es) | 2024-03-01 |
Family
ID=85507597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002060A MX2024002060A (es) | 2021-09-08 | 2022-09-06 | Composicion farmaceutica para tratar tumores solidos. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250222003A1 (https=) |
| EP (1) | EP4364742A4 (https=) |
| JP (1) | JP7445826B2 (https=) |
| KR (1) | KR20240056487A (https=) |
| CN (1) | CN117794544A (https=) |
| AU (1) | AU2022342537A1 (https=) |
| CA (1) | CA3227813A1 (https=) |
| MX (1) | MX2024002060A (https=) |
| WO (1) | WO2023038030A1 (https=) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110288115A1 (en) * | 2010-05-24 | 2011-11-24 | Avmedis Llc | Treatment of vagally-mediated spectrum disorders |
| KR20160061911A (ko) * | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| CN112472699A (zh) * | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
| US9174998B2 (en) * | 2013-12-25 | 2015-11-03 | Eisai R&D Management Co., Ltd. | (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound |
| CA2986999C (en) | 2015-06-23 | 2023-08-08 | Eisai R&D Management Co., Ltd. | Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide |
| US12303505B2 (en) * | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| EP4051278B1 (en) * | 2019-10-29 | 2025-12-17 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
-
2022
- 2022-09-06 MX MX2024002060A patent/MX2024002060A/es unknown
- 2022-09-06 US US18/293,848 patent/US20250222003A1/en active Pending
- 2022-09-06 JP JP2023546948A patent/JP7445826B2/ja active Active
- 2022-09-06 CA CA3227813A patent/CA3227813A1/en active Pending
- 2022-09-06 WO PCT/JP2022/033458 patent/WO2023038030A1/ja not_active Ceased
- 2022-09-06 EP EP22867352.1A patent/EP4364742A4/en active Pending
- 2022-09-06 KR KR1020247003704A patent/KR20240056487A/ko active Pending
- 2022-09-06 CN CN202280052902.2A patent/CN117794544A/zh active Pending
- 2022-09-06 AU AU2022342537A patent/AU2022342537A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240056487A (ko) | 2024-04-30 |
| JP7445826B2 (ja) | 2024-03-07 |
| WO2023038030A1 (ja) | 2023-03-16 |
| EP4364742A4 (en) | 2025-07-02 |
| JPWO2023038030A1 (https=) | 2023-03-16 |
| EP4364742A1 (en) | 2024-05-08 |
| CN117794544A (zh) | 2024-03-29 |
| TW202327613A (zh) | 2023-07-16 |
| AU2022342537A1 (en) | 2024-02-15 |
| CA3227813A1 (en) | 2023-03-16 |
| US20250222003A1 (en) | 2025-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fish | Fluoroquinolone adverse effects and drug interactions | |
| US20170157134A1 (en) | Combination therapy | |
| US20250161280A1 (en) | Combination therapy using azabicyclo compound for cancer | |
| US9814724B2 (en) | Antitumor effect potentiator and antitumor agent | |
| JP5911929B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| CA2861056A1 (en) | Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders | |
| JP2021505575A5 (https=) | ||
| US20150005262A1 (en) | Hypoxia activated prodrugs and mtor inhibitors for treating cancer | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| KR102128866B1 (ko) | 오로라 키나제 저해제를 사용하는 암 치료 방법 | |
| MX2024002060A (es) | Composicion farmaceutica para tratar tumores solidos. | |
| JP2024529485A (ja) | イミダゾ［１，２－ｂ］ピリダジニル化合物及びその使用 | |
| CA2816601A1 (en) | Dexamethasone combination therapy | |
| JP2012036166A (ja) | 内服液剤 | |
| RU2024102374A (ru) | Фармацевтическая композиция для лечения солидных опухолей | |
| CN116077478A (zh) | α-酮戊二酸在制备缓解化疗引起的胃肠道毒性药物中的应用 | |
| WO2014058785A1 (en) | Combination therapy | |
| MX2024008662A (es) | Compuestos de pirrolo[1,2-b]-2-piridazinona como agonistas del receptor de 5-hidroxitriptamina 4 (5-ht4). | |
| HRP20171927T1 (hr) | Farmaceutski pripravak koji sadrži (1r,4r)-6'-fluor-n,n-dimetil-4-fenil-4',9'-diidro-3'h-spiro[cikloheksan-1,1'-pirano-[3,4,b]indol]-4-amin i acetilsalicilnu kiselinu | |
| JP2012506404A (ja) | 片頭痛処置用組み合わせ剤 | |
| NZ757344A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| NZ743582A (en) | Treatment of chronic hand eczema | |
| NZ743582B2 (en) | Treatment of chronic hand eczema | |
| RU2007136896A (ru) | Фармацевтическая композиция, содержащая омегакарбоксиарилзамещенную дифенилмочевину, для лечения рака |